---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-424739"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2026-10-19T13:00:13+00:00"
generated_at: "2026-10-19T13:01:14.121849+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx settles DOJOLVI patent suit with Navinta; generic entry set for Jan 1, 2033

## Summary
- Settlement among Ultragenyx, Baylor Research Institute and Navinta LLC resolves ANDA patent litigation in the U.S. District Court for the District of New Jersey over DOJOLVI (triheptanoin).
- Navinta receives a non-exclusive, royalty-free license to market its generic DOJOLVI beginning January 1, 2033, extending to July 1, 2033 if pediatric exclusivity is granted.
- Litigation against other ANDA filers seeking generic DOJOLVI approval remains pending in the U.S. District Court for the District of New Jersey.
- No financial terms or payments disclosed; the settlement will be submitted to the U.S. FTC and Department of Justice as required by law.

## SEC filing metadata
- accession: 0001193125-26-424739
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2026-10-19T13:00:13+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000119312526424739/0001193125-26-424739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000119312526424739/rare-20261019.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-424739
- JSON: https://secwatch.observer/filing/0001193125-26-424739.json
- Plain text: https://secwatch.observer/filing/0001193125-26-424739.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.